Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=12 Podocyte Retinoids

Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
National Institute of Diabetes and Digestive and… Results Dec 2017 0.0% serious AE View details

Phase 3 N=8 Steroid Treatment for Kidney Disease

Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
National Institute of Diabetes and Digestive and… Results Oct 2011 37.5% serious AE View details

Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
National Institute of Diabetes and Digestive and… Results Feb 2016 20.0% serious AE View details

Phase 2 N=36 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Nephrotic Syndrome · Focal Segmental Glomerulosclerosis · Minimal Change Disease
Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants
Bristol-Myers Squibb Results Mar 2021 21.0% serious AE View details

Phase 2 N=43 Rituximab and Belimumab for Lupus Nephritis

Lupus Nephritis
Primary: Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96 — 9.1; 4.8; 22.7; 9.5 percentage of participants…
National Institute of Allergy and Infectious… Results Apr 2019 22.1% serious AE View details

Phase 2 N=63 Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Kidney Transplantation · Primary Focal Segmental Glomerulosclerosis (FSGS)
Primary: Percentage of Participants With Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss or Lost to Follow-up Through 3 Months Post Transplant…
Astellas Pharma Global Development, Inc. Results Jan 2022 50.8% serious AE View details